These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7. Jansen B, Vallera DA, Jaszcz WB, Nguyen D, Kersey JH. Cancer Res; 1992 Mar 01; 52(5):1314-21. PubMed ID: 1371092 [Abstract] [Full Text] [Related]
4. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855 [Abstract] [Full Text] [Related]
5. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA. Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284 [Abstract] [Full Text] [Related]
6. Efficient transplantation of human non-T-leukemia cells into nude mice and induction of complete regression of the transplanted distinct tumors by ricin A-chain conjugates of monoclonal antibodies SN5 and SN6. Hara H, Luo Y, Haruta Y, Seon BK. Cancer Res; 1988 Aug 15; 48(16):4673-80. PubMed ID: 2969282 [Abstract] [Full Text] [Related]
10. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5866-73. PubMed ID: 14676108 [Abstract] [Full Text] [Related]
12. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia. Fishwild DM, Aberle S, Bernhard SL, Kung AH. Cancer Res; 1992 Jun 01; 52(11):3056-62. PubMed ID: 1375534 [Abstract] [Full Text] [Related]
15. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice. de Kroon JF, de Paus RA, Kluin-Nelemans HC, Kluin PM, van Bergen CA, Munro AJ, Hale G, Willemze R, Falkenburg JH. Exp Hematol; 1996 Jul 01; 24(8):919-26. PubMed ID: 8690051 [Abstract] [Full Text] [Related]
16. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice. Flavell DJ, Warnes SL, Noss AL, Flavell SU. Br J Cancer; 2000 Dec 01; 83(12):1755-61. PubMed ID: 11104577 [Abstract] [Full Text] [Related]
18. An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins. Tazzari PL, de Totero D, Bolognesi A, Testoni N, Pileri S, Roncella S, Reato G, Stein H, Gobbi M, Stirpe F. Haematologica; 1999 Nov 01; 84(11):988-95. PubMed ID: 10553158 [Abstract] [Full Text] [Related]
19. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain. Fulton RJ, Uhr JW, Vitetta ES. Cancer Res; 1988 May 01; 48(9):2626-31. PubMed ID: 3258547 [Abstract] [Full Text] [Related]
20. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model]. Wang YD, Hu Y, Zhang L, Huang J, Sun CY. Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 01; 28(10):659-63. PubMed ID: 18399169 [Abstract] [Full Text] [Related] Page: [Next] [New Search]